Why cartilage cannot heal itself

Damaged cartilage in a joint does not mend the way a cut heals. Articular cartilage — the smooth hyaline tissue lining the ends of bones — contains no blood vessels and no nerve supply. Without blood flow, the body cannot mount the healing response that repairs muscle, ligament, or bone: there are no growth factors rushing to the site, no clot forming, no regenerative scaffold laying down. Left alone, a focal full-thickness defect tends to enlarge rather than fill, as repeated loading erodes the exposed area.

Clinicians use the International Cartilage Repair Society (ICRS) grading system to describe how deep a lesion runs. Grades 1 and 2 involve partial-thickness softening or fissuring — often manageable without surgery. Grade 3, where the defect extends beyond 50% of cartilage depth into the calcified layer, and Grade 4, where it penetrates the underlying subchondral bone, mark the threshold where surgical repair is most clearly warranted rather than conservative management alone.

Equally important is whether the damage is confined to a single contained area or has spread across the joint surface — a distinction that shapes the entire treatment pathway. MRI, including compositional imaging such as T2 mapping, is the standard tool for mapping defect depth, size, and bone involvement before any decision is reached.

The patient profile that suits cartilage repair

Most people who benefit from cartilage repair share a broadly similar clinical profile: typically under 50, active enough to have noticed a clear functional decline, and carrying a single contained defect rather than damage spread across the whole joint surface. That focal-versus-diffuse distinction shapes the entire pathway and is the most important filter before any repair option is considered.

Symptom burden matters as much as imaging. Surgery is generally appropriate only after a structured conservative programme — physiotherapy, load management, and appropriate analgesia — has failed to produce adequate relief. Patients who arrive at a surgical assessment without completing rehabilitation tend to have less favourable outcomes than those who have done so.

On the ICRS scale, Grade 3 and 4 lesions — those reaching and penetrating the subchondral bone, as described in the previous section — represent the clearest threshold for surgical consideration. The evidence base for repair at these severities is substantially stronger than for shallower damage.

Pre-operative MRI is the central assessment tool. The AMADEUS scoring system achieves approximately 0.70 sensitivity for matching defect severity against what is found during arthroscopy, a measure of how reliably the scan predicts the damage seen directly inside the joint. Compositional T2 mapping goes further: the T2 index of repair cartilage correlates with post-operative clinical outcomes (r ≈ 0.52), giving specialists a quantitative basis for both planning and monitoring progress.

Age is not a hard cut-off. Overall joint health, defect characteristics, activity level, and a patient's functional goals weigh more heavily than any single number.

How defect size shapes the technique

Once eligibility is established, defect area becomes the primary fork in the road. The clinical logic is direct: smaller lesions can be addressed with simpler single-stage procedures; larger areas require more biologically sophisticated strategies to achieve durable fill and adequate integration.

For lesions roughly under 2–4 cm², two single-stage options carry a solid evidence base. Osteochondral autograft transfer (OATS or mosaicplasty) transplants a cylindrical plug of healthy bone and cartilage from a low-load zone of the same joint — delivering genuine hyaline cartilage rather than stimulating a substitute. Marrow stimulation techniques such as microfracture occupied a similar size bracket historically, but current evidence shows the fibrocartilage they produce tends to break down at two to three years, and the drilling process can damage the subchondral bone plate in ways that may compromise any future repair. Microfracture is therefore no longer a first-line modern recommendation, even for small defects.

At 3 cm² and above, cell-based repair carries the stronger evidence base. The SUMMIT randomised trial found that MACI produced superior KOOS pain and function scores versus microfracture at both two and five years for defects of this size. MACI is a two-stage process — a cartilage biopsy is taken first, cells are cultured, then re-implanted on a collagen membrane — making it resource-intensive and dependent on specialist infrastructure.

A technically simpler single-stage alternative in this size range is autologous minced cartilage implantation. In a five-year series with a mean defect area of 3.5 cm², 75% of patients reached a clinically meaningful improvement on the IKDC score and only 3.5% required revision surgery — offering a useful option where two-stage cell culture is not accessible.

For post-traumatic or very large defects where autograft tissue is insufficient, fresh osteochondral allograft (OCA) is an established option backed by long-term follow-up data.

When cartilage repair is not the right path

Not every patient with cartilage pain is a repair candidate, and recognising this early points toward the correct pathway rather than a failed one.

The most clinically significant dividing line is focal versus diffuse disease. Every repair technique — whether autograft, cell-based, or injectable scaffold — depends on healthy surrounding cartilage to anchor and integrate the repair. Once osteoarthritis has eroded the joint surface broadly, those intact borders no longer exist. One clinical framework describes the situation plainly: in diffuse osteoarthritis there are no pristine edges to build from and no healthy margins to contain the repair. Focal repair in this setting is contraindicated; it lacks the structural foundation the technique requires.

Active inflammatory arthritis and significant underlying bone loss similarly place a patient outside the scope of restorative procedures, as the joint environment cannot support graft integration or biological healing.

A practical map for understanding where repair fits is the PRRR framework — Preserve, Repair, Regenerate, Replace. Cartilage repair occupies the middle two zones of that continuum. When disease has progressed past those stages, joint replacement is not a treatment failure; it is the appropriate and logical next step in the same care pathway.

Knowing which zone a patient's joint sits in is the productive outcome of a specialist assessment. It identifies which tool is genuinely within reach — and, where repair is no longer realistic, removes uncertainty and moves the conversation toward the option most likely to restore function.

The joint factors that must be treated alongside

Fixing the cartilage alone is rarely sufficient. The mechanical environment surrounding the repair site matters just as much as the repair technique itself — and when problems in that environment go uncorrected, the repair is exposed to the same forces that caused or accelerated the damage in the first place.

Correcting the alignment of the leg is one of the most concrete examples. In patients with more than 5° of varus (bow-legged) alignment, a systematic review of 2,267 patients found that adding a corrective osteotomy to cartilage repair reduced reoperation rates from approximately 47% to 17%, alongside measurably better pain and function scores. Osteotomy in this context acts as a load-distribution adjunct — its role is to shift weight away from the damaged compartment so the repair is not immediately overloaded. Without it, a technically sound repair can still fail.

Ligament instability and meniscal deficiency carry the same logic: both place abnormal load on the repair site, and both should be addressed at the same time rather than deferred. Staged treatment risks the repair deteriorating before the secondary problem is resolved.

Before surgery, completing an adequate neuromuscular rehabilitation programme matters too — patients who are stronger and better conditioned going into the procedure tend to recover more predictably.

For patients whose cartilage damage is on the back of the kneecap (the patellofemoral joint), a concern sometimes raised at assessment is patellar shape — specifically whether an unusually shallow or differently formed kneecap (patellar dysplasia, classified by Wiberg type) might compromise the repair. The evidence here is broadly reassuring: patellar dysplasia does not appear to significantly affect patient-reported outcomes or graft survival after cell-based repair at mid-term follow-up, and clinicians should not automatically rule out patellofemoral candidates on that basis alone.

Across all of these decisions — age, defect size, access to two-stage cell-culture procedures, and cost — explicit shared decision-making with a specialist is the appropriate route. Search MSK lists cartilage specialists across the UK who can assess the full picture and discuss what a realistic plan looks like for an individual joint.

Finding the right specialist for your situation

By this point, a reader is better placed than most to evaluate a specialist recommendation. Three questions serve any cartilage consultation well: does the clinician offer the full technique range relevant to the defect size — from marrow stimulation through to cell-based or injectable scaffold options? Will alignment, ligament stability, and meniscal health be assessed alongside the defect itself, not treated as separate concerns? And if the recommended approach sits at the resource-intensive end — two-stage cell culture, for instance — is requesting a second opinion a reasonable step?

Those questions are institution-agnostic and apply wherever in the UK a patient is seeking advice. Search MSK lists cartilage repair and restoration specialists across the UK — covering knee, hip, ankle, and other joints — and can be filtered by region and by the specific techniques a clinician offers, so the starting point is matching technique scope to defect profile.

For patients whose imaging already confirms a focal Grade 3 or 4 lesion and who have worked through conservative management without adequate improvement, the clinical vocabulary from this article is now in place — the remaining task is putting the right questions to a specialist and judging whether the answer fits.